Orthopedic Bone Articles & Analysis
23 news found
The company intends to pursue multiple applications in the distal extremity, trauma, sports, reconstruction, pediatrics, and spine segments. OSSIOfiber® Intelligent Bone Regeneration Technology Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber® Intelligent Bone Regeneration Technology is a first-of-its-kind ...
P-15L Bone Graft is based on a small biomimetic peptide (P-15) technology developed by Cerapedics to support bone growth, and is designed to be used as a substitute for autologous bone. In 2015, the company’s first-generation bone graft became the first bone graft to be approved for use in the cervical ...
The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate compared to allograft plus local bone. ...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). ...
About Cerapedics Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone ...
Sawbones is the world leader in supplying bone surrogate materials to the orthopedic industry and is consistently used to perform bench tests on new devices. ...
i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation. About Cerapedics Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic ...
” i-FACTOR+ MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. Cerapedics initial P-15 technology product, i-FACTOR Peptide Enhanced Bone Graft, was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids ...
In spinal fusion procedures, surgeons use a bone graft to join and stabilize vertebrae. i-FACTOR Peptide Enhanced Bone Graft was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions private, ...
IlluminOss offers a unique and disruptive technology for the orthopedic trauma market. The Company's Photodynamic Bone Stabilization System is a minimally invasive approach for fracture repair and stabilization through a patient-specific intramedullary implant. ...
Silver Bullet Therapeutics, Inc., a privately-held medical device company, announced today that it has received recommendation for CE Mark approval for the commercial sale of its antimicrobial OrthoFuzIon™ Bone Screw System in the European Union for orthopedic reduction and internal fixation procedures anywhere in the body. Over the next few months, Silver ...
” Cerapedics commercialized i-FACTOR Bone Graft beginning in 2016. The drug-device combination is based on synthetic small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. ...
Edidin brings to Procyrion more than 25 years of experience as a global medical device leader, with previous leadership in the development and commercial introduction of devices in the long bone orthopedic, spinal fixation and ablation, and catheter instrumentation areas. ...
HCCP technology serves as the platform for MMI’s bone regeneration product, Osteo-P™ Bone Graft Substitute (BGS). ...
“IlluminOss is truly an innovative addition to fragility fracture treatment and we have been receiving outstanding feedback from our orthopedic surgeon customers regarding its potential to make a difference for patients with poor quality bone. ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions Zetagen Therapeutics, ...
IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the IlluminOss Photodynamic Bone Stabilization System has received additional clinical clearance and is now indicated by the U.S. ...
IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received U.S. Food and Drug Administration (FDA) de novo clearance for the IlluminOss Bone Stabilization System for treatment of impending and actual pathological fractures of the humerus, radius and ...
Silver Bullet Therapeutics, Inc., a privately held medical device company that has developed an antimicrobial technology for implantable medical devices such as orthopedic bone screws, reported today the results of a study testing the “Time Kill” and “Adherence” effectiveness of its CE-marked OrthoFuzIon® Antimicrobial ...